Literature DB >> 17678634

Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder.

Dara M Cannon1, Masanori Ichise, Denise Rollis, Jacqueline M Klaver, Shilpa K Gandhi, Dennis S Charney, Husseini K Manji, Wayne C Drevets.   

Abstract

BACKGROUND: Altered serotonergic function is thought to play a role in the pathophysiology of major depressive episodes based upon evidence from neuroimaging, pharmacological, postmortem and genetic studies. It remains unclear, however, whether depressed samples that differ with respect to having shown a unipolar versus a bipolar illness course also would show distinct patterns of abnormalities within the serotonergic system. The current study compared serotonin transporter (5-HTT) binding between unipolar-depressives (MDD), bipolar-depressives (BD) and healthy-controls (HC) to assess whether the abnormalities in 5-HTT binding recently found in depressed subjects with BD extend to depressed subjects with MDD.
METHODS: The 5-HTT binding-potential (BP) measured using positron emission tomography (PET) and [(11)C]DASB was compared between unmedicated, depressed subjects with MDD (n = 18) or BD (n = 18) and HC (n = 34).
RESULTS: Relative to the healthy group both MDD and BD groups showed significantly increased 5-HTT BP in the thalamus (24%, 14%, respectively), insula (15%) and striatum (12%). The unipolar-depressives had elevated 5-HTT BP relative to both BD and HC groups in the vicinity of the periaqueductal gray (PAG, 20%, 22%, respectively). The bipolar-depressives had reduced 5-HTT BP relative to both HC and MDD groups in the vicinity of the pontine raphe nuclei. Depression-severity correlated negatively with 5-HTT BP in the thalamus in MDD-subjects.
CONCLUSIONS: The depressed phases of MDD and BD both were associated with elevated 5-HTT binding in the insula, thalamus and striatum, but showed distinct abnormalities in the brainstem. The latter findings conceivably could underlie differences in the patterns of illness symptoms and pharmacological sensitivity observed between MDD and BD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678634     DOI: 10.1016/j.biopsych.2007.03.016

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  77 in total

1.  Intuition, insight, and the right hemisphere: Emergence of higher sociocognitive functions.

Authors:  Simon M McCrea
Journal:  Psychol Res Behav Manag       Date:  2010-03-03

2.  Central serotonin transporter levels are associated with stress hormone response and anxiety.

Authors:  Matthias Reimold; Astrid Knobel; Michael A Rapp; Anil Batra; Klaus Wiedemann; Andreas Ströhle; Anke Zimmer; Peter Schönknecht; Michael N Smolka; Daniel R Weinberger; David Goldman; Hans-Jürgen Machulla; Roland Bares; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

3.  Length of axons expressing the serotonin transporter in orbitofrontal cortex is lower with age in depression.

Authors:  Grazyna Rajkowska; Gouri Mahajan; Beata Legutko; Lavanya Challagundla; Michael Griswold; Paul R Albert; Mireille Daigle; Jose J Miguel-Hidalgo; Mark C Austin; Randy D Blakely; David C Steffens; Craig A Stockmeier
Journal:  Neuroscience       Date:  2017-07-13       Impact factor: 3.590

Review 4.  Positron emission tomography molecular imaging in late-life depression.

Authors:  Kentaro Hirao; Gwenn S Smith
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

Review 5.  Brain PET Imaging: Value for Understanding the Pathophysiology of HIV-associated Neurocognitive Disorder (HAND).

Authors:  Sanhita Sinharay; Dima A Hammoud
Journal:  Curr HIV/AIDS Rep       Date:  2019-02       Impact factor: 5.071

6.  Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder.

Authors:  Jeffrey M Miller; Natalie Hesselgrave; R Todd Ogden; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  Biol Psychiatry       Date:  2013-03-01       Impact factor: 13.382

7.  Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.

Authors:  D M Cannon; J K Klaver; S K Gandhi; G Solorio; S A Peck; K Erickson; N Akula; J Savitz; W C Eckelman; M L Furey; B J Sahakian; F J McMahon; W C Drevets
Journal:  Mol Psychiatry       Date:  2010-03-30       Impact factor: 15.992

8.  Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder.

Authors:  Jeffrey M Miller; Erin L Kinnally; R Todd Ogden; Maria A Oquendo; J John Mann; Ramin V Parsey
Journal:  Synapse       Date:  2009-07       Impact factor: 2.562

9.  The relation of developmental changes in brain serotonin transporter (5HTT) and 5HT1A receptor binding to emotional behavior in female rhesus monkeys: effects of social status and 5HTT genotype.

Authors:  M Embree; V Michopoulos; J R Votaw; R J Voll; J Mun; J S Stehouwer; M M Goodman; M E Wilson; M M Sánchez
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.